Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial
Bruno Maranda, Sébastien M. Labbé, Magali Lurquin, Pascal Brabant, Alexandre Fugère, Jean‐François Larrivée, Djordje Grbic, Annie Leroux, Frédéric Leduc, Andrés Finzi, Simon Gaudreau, Yolandi Swart
Topics & Concepts
Coronavirus disease 2019 (COVID-19)PlaceboMedicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Double blindRandomized controlled trialPhase (matter)Internal medicineAnesthesiaVirologyAlternative medicinePathologyChemistryDiseaseOutbreakInfectious disease (medical specialty)Organic chemistrySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19